Kay Tetzlaff, M.D. has over 30 years of experience in the development of new therapeutics, including over 23 years at Boerhinger Ingelheim where he most recently served as Corporate VP of Inflammation and Respiratory Medicine. Previously at Boehringer Ingelheim, he had roles of increasing responsibility in respiratory clinical research and medical affairs. Among the products he worked on, Dr. Tetzlaff was the medical lead for the successful development of nintedanib for Systemic Sclerosis and Progressive Pulmonary Fibrosis that enabled expansion of market share and revenues of nintedanib across indications. Dr. Tetzlaff received his MD from the University of Hamburg and completed a fellowship in Pulmonary and Critical Care.
